Metaproteomics, LLC

Metaprotemics, LLC

Robert Lerman

Matthew L Tripp

Jeffrey S Bland

John G Babish

Terrence M Howell

Gary K Darland

Daniel O Lukaczer

DeAnn J Liska

Veera Konda

Amy J Hall

Anu Desai

Deann J Liska

A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.

Compositions that treat or inhibit pathological conditions associated with inflammatory response

Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response

A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandin selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops.

Modulation of inflammation by hops fractions and derivatives

Compositions of reduced isoalpha acids, vitamins and minerals are disclosed as well as methods of using the same for the treatment of autoimmune diseases. Additional combinations including other compounds are also contemplated. Synergistic properties and methods exploiting such synergy are also disclosed.

Treatment modalities for autoimmune diseases

A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops.

The invention provides hops () extracts or derivatives thereof for use in treating a patient prophylactically and/or therapeutically for ulcerogenic-type disorders of the stomach and/or intestines. The ulcerogenic disorders can be of the type chemically induced, environmentally-induced, infection-induced, and/or stress-induced. The invention also provides a pharmaceutical composition comprising an active amount of hops extracts or derivatives thereof, in combination with an analgesic compound and/or an anti-inflammatory compound. The invention further provides for use of hops extracts or derivatives thereof, significantly reducing and/or therapeutically treating ulcerogenic-type disorders of the stomach and/or intestines.

Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity

Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity

Growing community of inventors

Gig Harbor, WA, United States of America

Robert Lerman